SWK Holdings focuses on pharmaceutical development, manufacturing and intellectual property licensing business. Co.'s operations comprise two reportable segments: Finance Receivables, which provides customized financing solutions to a range of life science companies, institutions and inventors, and focuses on commercial-stage products and related intellectual property through royalty purchases and financings, as well as through commercialized products; and Pharmaceutical Development, in which through its subsidiary, Enteris BioPharma, Inc., provides formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform. When considering the SWK Holdings Corp stock dividend history, we have taken known splits into account, such that the SWKH dividend history is presented on a split-adjusted ("apples to apples") basis. SWK Holdings Corp dividend history is presented both in graphical/chart form, and as a SWKH dividend history data table along the right-hand column.
|
SWKH Stock Dividend HistoryThe SWKH dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable SWKH historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the SWKH dividend history record. Also see the SWKH stock dividend history data table along the right-hand column below. |
|
|
Strong Buy (4.00 out of 4) 80th percentile
(ranked higher than approx. 80% of all stocks covered)
Analysts' Target Price: SWKH Forecast Based on data provided by Zacks Investment Research via Quandl.com |